In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...

Venture capital firms incubate, grow and finance dozens of new drug companies each year. Follow the money they channel into ...

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...

Built around research by Stanford scientist Carolyn Bertozzi and MIT researcher Jessica Stark, Valora Therapeutics is ...

Biotech company creator Versant Ventures has launched a new startup with an ambitious plan to combine four different ways of ...

Negative results from a Huntington’s trial add to a calamitous year for Sage, which last month decided to overhaul its ...

Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

Analysts see Trump’s victory raising the high-profile legislation’s chances of becoming law. But the realities of a lame duck ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless ...